A Response Surface Analysis for the Interaction Between Ciprofol and Sevoflurane

ConditionInduction of General Anesthesia

Trial statusNot yet recruiting

Trial phasePhase 4

Trial typeInterventional

Biological sexAll

Age18-60

SponsorFeng Gao

About this trial

Intravenous and inhalation combined anesthesia is a commonly used method for maintaining general anesthesia in clinical practice. This study aims to explore the interaction between ciprofol and sevoflurane. By employing response surface methodology, we constructed a three-dimensional pharmacodynamic interaction surface for various dose combinations of ciprofol and sevoflurane. This approach allows us to determine the nature of the interaction between the two drugs at any given level, thereby providing a ciprofol understanding of the dose-response relationship when ciprofol and sevoflurane are used in combination. This knowledge will serve as a theoretical basis for rational drug administration during surgery.

Eligibility criteria

Qualifiers

Patients undergoing elective general anesthesia and non-cardiac surgery;

Age 18-60 years old, gender is not limited;

ASA I or II level;

Body mass index (BMI) 18-30 kg/m2

Disqualifiers

Preoperative assessment of potential difficult airway risk;

Airway hyperreactivity;

There is disease of the central nervous system or cardiovascular system;

Currently using drugs that may alter the pharmacokinetics and pharmacokinetics of the drug under study;

Trial design

Treatments tested in this trial

Sevoflurane 0 + different doses of ciprofol
Sevoflurane 0.7% + different doses of ciprofol
Sevoflurane 1.0% + different doses of ciprofol 0.05
Sevoflurane 1.5% + differnet doses of ciprofol
Sevoflurane 2.0% + different doses of ciprofol
Sevoflurane 2.5% + different doses of ciprofol
Ciprofol 0 + different end-expiratory concentration of sevoflurane
Ciprofol 0.05mg/kg + different end-expiratory concentration of sevoflurane
Ciprofol 0.1mg/kg + different end-expiratory concentration of sevoflurane
Ciprofol 0.2 mg/kg + different end-expiratory concentration of sevoflurane
Ciprofol 0.3 mg/kg + different end-expiratory concentration of sevoflurane
Ciprofol 0.4 mg/kg + different end-expiratory concentration of sevoflurane

Treatment groups

300 Participants

are divided into 2 treatment groups

Locations

This trial has no locations

Sponsors and collaborators

Feng Gao

Lead sponsor

Tongji Hospital

Sponsor institution

Sichuan Provincial People's Hospital

Collaborator

Source ClinicalTrials.gov